Tscan therapeutics to participate in upcoming investor conferences

Waltham, mass., sept. 22, 2022 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr) engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced that management will participate in the following upcoming investor conferences:

TCRX Ratings Summary

TCRX Quant Ranking